

-----Original Message-----

From: [REDACTED]@dh.gsi.gov.uk [mailto:[REDACTED]@dh.gsi.gov.uk] On Behalf Of  
mbnicesponsorteam@dh.gsi.gov.uk

Sent: 20 July 2011 08:19

To: TA Comm B

Cc: [REDACTED]@dh.gsi.gov.uk

Subject: NICE Multiple Technology Appraisal - mCRC review - Assessment Report  
Consultation on Cetuximab, bevacizumab and panitumumab monotherapy for the  
treatment of metastatic colorectal cancer that has progressed after first line  
chemotherapy (review of TA 150...

Dear NICE

Thank you for the opportunity to comment on the technical content of the  
assessment report for the above multiple technology appraisal.

I wish to confirm that the Department of Health has no substantive comments  
to make regarding this consultation.

Many thanks and best wishes

[REDACTED]  
NICE Sponsor Team  
Department of Health